Aperio Group’s Takeda Pharmaceutical TAK Stock Holding History

Aperio Group’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$20.2M	Sell	1,111,580 -132,202	-11%	-$2.32M	0.06%	308
2020 Q3	$22.2M	Buy	1,243,782 +213,340	+21%	+$3.88M	0.07%	249
2020 Q2	$18.5M	Buy	1,030,442 +279,898	+37%	+$5.02M	0.07%	279
2020 Q1	$11.4M	Sell	750,544 -264,687	-26%	-$4.8M	0.05%	371
2019 Q4	$20M	Buy	1,015,231 +187,958	+23%	+$3.6M	0.07%	293
2019 Q3	$14.2M	Buy	827,273 +229,309	+38%	+$3.97M	0.06%	370
2019 Q2	$10.6M	Sell	597,964 -284,447	-32%	-$5.18M	0.04%	457
2019 Q1	$18M	Buy	882,411 +643,224	+269%	+$12.9M	0.08%	287
2018 Q4	$4.02M	Buy	+239,187	New	+$4.04M	0.02%	723

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Aperio Group's TAK Position: Q4 2020 in Review

Aperio Group reduced its Takeda Pharmaceutical (TAK) stake by 11% in Q4 2020, selling an estimated $2.32M and leaving 1,111,580 shares worth $20.2M. The position accounts for 0.06% of the portfolio, ranked #308.

Aperio Group first reported a position in TAK in Q4 2018 and has held it in 9 quarters since. The position peaked at $22.2M in Q3 2020. 313 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

Aperio Group held 1,111,580 shares of Takeda Pharmaceutical worth $20.2M as of Q4 2020.
Aperio Group sold 132,202 Takeda Pharmaceutical shares in Q4 2020, an estimated $2.32M.
Takeda Pharmaceutical made up 0.06% of Aperio Group's portfolio in Q4 2020, its #308 holding.
Aperio Group first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 9 quarters since.
Aperio Group's Takeda Pharmaceutical position peaked at $22.2M in Q3 2020.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.